# Switch Therapeutics

> Switch Therapeutics is a South San Francisco preclinical biotech building conditionally activated siRNA (CASi) therapies that only switch on inside the cell types where they're needed. The platform - born from research at Caltech, Harvard and City of Hope - aims to make RNA interference safe enough for the brain, with a lead program targeting APOE for Alzheimer's disease.

- **Founded:** 2020
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Dee Datta (Co-Founder & CEO), Si-ping Han, Ph.D. (Co-Founder & CTO)
- **Team size:** ~30 employees
- **Products:** CASi Platform, CASi-APOE, Microglia-Selective Program, Astrocyte-Selective Program, Tau Program
- **Notable:** Emerged from stealth in March 2023 with $52M Series A., First-of-its-kind CASi (conditionally activated siRNA) platform., Named first development candidate CASi-APOE in December 2024.

## Products & services

- **CASi Platform** — Conditionally Activated siRNAs - a proprietary class of nucleic acid therapeutics that combine single- and double-stranded RNA properties in one molecule, enabling self-delivery and cell-state-specific RNAi activation.
- **CASi-APOE** — Lead development candidate - a liver-sparing APOE-targeting RNAi therapy aimed at Alzheimer's disease in APOE4 carriers.
- **Microglia-Selective Program** — Earlier-stage CASi program designed to knock down disease targets specifically in microglia.
- **Astrocyte-Selective Program** — Earlier-stage CASi program designed for selective gene silencing in astrocytes.
- **Tau Program** — A planned second development candidate targeting tau production for tauopathies including PSP and Alzheimer's disease.

## Achievements

- Emerged from stealth in March 2023 with $52M Series A.
- First-of-its-kind CASi (conditionally activated siRNA) platform.
- Named first development candidate CASi-APOE in December 2024.
- Recruited Alzheimer's expert David M. Holtzman, M.D. to Scientific Advisory Board.
- Backed by a syndicate including Insight Partners, UCB, Eli Lilly and CRV.

## Latest updates

- **2024-12** — Announced first development candidate CASi-APOE and appointed Dr. David M. Holtzman to its SAB.
- **2024** — Advanced microglia- and astrocyte-selective CASi programs.
- **2023-03** — Launched from stealth with $52M Series A.
- **2022** — Moved from MBC Biolabs incubator to dedicated South San Francisco facilities.

## Links

- Website: https://switchthera.com
- LinkedIn: https://www.linkedin.com/company/switch-therapeutics

---

Profile page: https://yespress.io/switch-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-27